ID   HMGB1_RAT               Reviewed;         215 AA.
AC   P63159; P07155; P27109; P27428; Q548R9;
DT   01-APR-1988, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 2.
DT   24-JUL-2024, entry version 169.
DE   RecName: Full=High mobility group protein B1;
DE   AltName: Full=Amphoterin;
DE   AltName: Full=Heparin-binding protein p30;
DE   AltName: Full=High mobility group protein 1;
DE            Short=HMG-1;
GN   Name=Hmgb1; Synonyms=Hmg-1, Hmg1;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Sprague-Dawley; TISSUE=Liver;
RX   PubMed=3684582; DOI=10.1093/nar/15.21.9077;
RA   Paonessa G., Frank R., Cortese R.;
RT   "Nucleotide sequence of rat liver HMG1 cDNA.";
RL   Nucleic Acids Res. 15:9077-9077(1987).
RN   [2]
RP   SEQUENCE REVISION.
RA   Bianchi M.;
RL   Submitted (DEC-1988) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], PARTIAL PROTEIN SEQUENCE, SUBCELLULAR LOCATION,
RP   AND FUNCTION.
RX   PubMed=1885601; DOI=10.1016/s0021-9258(18)55361-8;
RA   Merenmies J., Pihlaskari R., Laitinen J., Wartiovaara J., Rauvala H.;
RT   "30-kDa heparin-binding protein of brain (amphoterin) involved in neurite
RT   outgrowth. Amino acid sequence and localization in the filopodia of the
RT   advancing plasma membrane.";
RL   J. Biol. Chem. 266:16722-16729(1991).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Sprague-Dawley; TISSUE=Kidney;
RA   Ito T., Suzuki A., Horimoto N., Imai E., Hori M.;
RT   "Amphoterin is associated with the development of the kidney.";
RL   Submitted (JUN-2000) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Kidney, Prostate, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PROTEIN SEQUENCE OF 2-21, SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=2461949; DOI=10.1083/jcb.107.6.2293;
RA   Rauvala H., Merenmies J., Pihlaskari R., Korkolainen M., Huhtala M.L.,
RA   Panula P.;
RT   "The adhesive and neurite-promoting molecule p30: analysis of the amino-
RT   terminal sequence and production of antipeptide antibodies that detect p30
RT   at the surface of neuroblastoma cells and of brain neurons.";
RL   J. Cell Biol. 107:2293-2305(1988).
RN   [7]
RP   DNA-BINDING.
RX   PubMed=2922595; DOI=10.1126/science.2922595;
RA   Bianchi M.E., Beltrame M., Paonessa G.;
RT   "Specific recognition of cruciform DNA by nuclear protein HMG1.";
RL   Science 243:1056-1059(1989).
RN   [8]
RP   FUNCTION.
RX   PubMed=7592757; DOI=10.1074/jbc.270.43.25752;
RA   Hori O., Brett J., Slattery T., Cao R., Zhang J., Chen J.X., Nagashima M.,
RA   Lundh E.R., Vijay S., Nitecki D.;
RT   "The receptor for advanced glycation end products (RAGE) is a cellular
RT   binding site for amphoterin. Mediation of neurite outgrowth and co-
RT   expression of rage and amphoterin in the developing nervous system.";
RL   J. Biol. Chem. 270:25752-25761(1995).
RN   [9]
RP   INTERACTION WITH PTPRZ1.
RX   PubMed=9507007; DOI=10.1074/jbc.273.12.6998;
RA   Milev P., Chiba A., Haring M., Rauvala H., Schachner M., Ranscht B.,
RA   Margolis R.K., Margolis R.U.;
RT   "High affinity binding and overlapping localization of neurocan and
RT   phosphacan/protein-tyrosine phosphatase-zeta/beta with tenascin-R,
RT   amphoterin, and the heparin-binding growth-associated molecule.";
RL   J. Biol. Chem. 273:6998-7005(1998).
RN   [10]
RP   FUNCTION.
RX   PubMed=10866811; DOI=10.1046/j.1432-1327.2000.01450.x;
RA   Stros M., Cherny D., Jovin T.M.;
RT   "HMG1 protein stimulates DNA end joining by promoting association of DNA
RT   molecules via their ends.";
RL   Eur. J. Biochem. 267:4088-4097(2000).
RN   [11]
RP   FUNCTION.
RX   PubMed=10952726; DOI=10.1084/jem.192.4.565;
RA   Andersson U., Wang H., Palmblad K., Aveberger A.C., Bloom O.,
RA   Erlandsson-Harris H., Janson A., Kokkola R., Zhang M., Yang H.,
RA   Tracey K.J.;
RT   "High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine
RT   synthesis in human monocytes.";
RL   J. Exp. Med. 192:565-570(2000).
RN   [12]
RP   FUNCTION.
RX   PubMed=10830965; DOI=10.1038/35012626;
RA   Taguchi A., Blood D.C., del Toro G., Canet A., Lee D.C., Qu W., Tanji N.,
RA   Lu Y., Lalla E., Fu C., Hofmann M.A., Kislinger T., Ingram M., Lu A.,
RA   Tanaka H., Hori O., Ogawa S., Stern D.M., Schmidt A.M.;
RT   "Blockade of RAGE-amphoterin signalling suppresses tumour growth and
RT   metastases.";
RL   Nature 405:354-360(2000).
RN   [13]
RP   PHOSPHOLIPID-BINDING.
RX   PubMed=11154118;
RA   Rouhiainen A., Imai S., Rauvala H., Parkkinen J.;
RT   "Occurrence of amphoterin (HMG1) as an endogenous protein of human
RT   platelets that is exported to the cell surface upon platelet activation.";
RL   Thromb. Haemost. 84:1087-1094(2000).
RN   [14]
RP   DNA-BINDING, AND DOMAIN.
RX   PubMed=11513603; DOI=10.1021/bi0100900;
RA   Mueller S., Bianchi M.E., Knapp S.;
RT   "Thermodynamics of HMGB1 interaction with duplex DNA.";
RL   Biochemistry 40:10254-10261(2001).
RN   [15]
RP   FUNCTION, AND LIGAND FOR AGER RECEPTOR.
RX   PubMed=12183440;
RA   Huttunen H.J., Fages C., Kuja-Panula J., Ridley A.J., Rauvala H.;
RT   "Receptor for advanced glycation end products-binding COOH-terminal motif
RT   of amphoterin inhibits invasive migration and metastasis.";
RL   Cancer Res. 62:4805-4811(2002).
RN   [16]
RP   FUNCTION.
RX   PubMed=12486007; DOI=10.1093/emboj/cdf692;
RA   Bonaldi T., Langst G., Strohner R., Becker P.B., Bianchi M.E.;
RT   "The DNA chaperone HMGB1 facilitates ACF/CHRAC-dependent nucleosome
RT   sliding.";
RL   EMBO J. 21:6865-6873(2002).
RN   [17]
RP   SUBCELLULAR LOCATION.
RX   PubMed=12110890; DOI=10.1038/nature00858;
RA   Scaffidi P., Misteli T., Bianchi M.E.;
RT   "Release of chromatin protein HMGB1 by necrotic cells triggers
RT   inflammation.";
RL   Nature 418:191-195(2002).
RN   [18]
RP   SUBCELLULAR LOCATION, MUTAGENESIS OF 28-LYS--LYS-30 AND 182-LYS--LYS-184,
RP   AND INTERACTION WITH XPO1.
RX   PubMed=14532127; DOI=10.1093/emboj/cdg516;
RA   Bonaldi T., Talamo F., Scaffidi P., Ferrera D., Porto A., Bachi A.,
RA   Rubartelli A., Agresti A., Bianchi M.E.;
RT   "Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it
RT   towards secretion.";
RL   EMBO J. 22:5551-5560(2003).
RN   [19]
RP   DOMAIN.
RX   PubMed=15379539; DOI=10.1021/bi049364k;
RA   Knapp S., Mueller S., Digilio G., Bonaldi T., Bianchi M.E., Musco G.;
RT   "The long acidic tail of high mobility group box 1 (HMGB1) protein forms an
RT   extended and flexible structure that interacts with specific residues
RT   within and between the HMG boxes.";
RL   Biochemistry 43:11992-11997(2004).
RN   [20]
RP   SUBCELLULAR LOCATION, CHROMATIN-BINDING, AND MUTAGENESIS OF PHE-38; PHE-103
RP   AND ILE-122.
RX   PubMed=15808513; DOI=10.1016/j.molcel.2005.03.005;
RA   Agresti A., Scaffidi P., Riva A., Caiolfa V.R., Bianchi M.E.;
RT   "GR and HMGB1 interact only within chromatin and influence each other's
RT   residence time.";
RL   Mol. Cell 18:109-121(2005).
RN   [21]
RP   DISULFIDE BRIDGE, REDOX FORMS, AND MUTAGENESIS OF CYS-23; CYS-45 AND
RP   CYS-106.
RX   PubMed=16962095; DOI=10.1016/j.yexcr.2006.07.020;
RA   Hoppe G., Talcott K.E., Bhattacharya S.K., Crabb J.W., Sears J.E.;
RT   "Molecular basis for the redox control of nuclear transport of the
RT   structural chromatin protein Hmgb1.";
RL   Exp. Cell Res. 312:3526-3538(2006).
RN   [22]
RP   ACETYLATION AT LYS-3.
RX   PubMed=17269659; DOI=10.1021/bi0614479;
RA   Ugrinova I., Mitkova E., Moskalenko C., Pashev I., Pasheva E.;
RT   "DNA bending versus DNA end joining activity of HMGB1 protein is modulated
RT   in vitro by acetylation.";
RL   Biochemistry 46:2111-2117(2007).
RN   [23]
RP   FUNCTION.
RX   PubMed=18277947; DOI=10.1097/shk.0b013e3181672495;
RA   Zhang L.T., Yao Y.M., Dong Y.Q., Dong N., Yu Y., Sheng Z.Y.;
RT   "Relationship between high-mobility group box 1 protein release and T-cell
RT   suppression in rats after thermal injury.";
RL   Shock 30:449-455(2008).
RN   [24]
RP   INTERACTION WITH BECN1, AND MUTAGENESIS OF CYS-23; CYS-45 AND CYS-106.
RX   PubMed=20819940; DOI=10.1083/jcb.200911078;
RA   Tang D., Kang R., Livesey K.M., Cheh C.W., Farkas A., Loughran P.,
RA   Hoppe G., Bianchi M.E., Tracey K.J., Zeh H.J. III, Lotze M.T.;
RT   "Endogenous HMGB1 regulates autophagy.";
RL   J. Cell Biol. 190:881-892(2010).
RN   [25]
RP   FUNCTION, LIGAND FOR TLR4:LY96 RECEPTOR COMPLEX, AND MUTAGENESIS OF
RP   CYS-106.
RX   PubMed=20547845; DOI=10.1073/pnas.1003893107;
RA   Yang H., Hreggvidsdottir H.S., Palmblad K., Wang H., Ochani M., Li J.,
RA   Lu B., Chavan S., Rosas-Ballina M., Al-Abed Y., Akira S., Bierhaus A.,
RA   Erlandsson-Harris H., Andersson U., Tracey K.J.;
RT   "A critical cysteine is required for HMGB1 binding to Toll-like receptor 4
RT   and activation of macrophage cytokine release.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:11942-11947(2010).
RN   [26]
RP   REDOX FORMS, FUNCTION, INTERACTION WITH CXCL12, SUBCELLULAR LOCATION, AND
RP   OXIDATION AT CYS-106.
RX   PubMed=22869893; DOI=10.1084/jem.20120189;
RA   Venereau E., Casalgrandi M., Schiraldi M., Antoine D.J., Cattaneo A.,
RA   De Marchis F., Liu J., Antonelli A., Preti A., Raeli L., Shams S.S.,
RA   Yang H., Varani L., Andersson U., Tracey K.J., Bachi A., Uguccioni M.,
RA   Bianchi M.E.;
RT   "Mutually exclusive redox forms of HMGB1 promote cell recruitment or
RT   proinflammatory cytokine release.";
RL   J. Exp. Med. 209:1519-1528(2012).
RN   [27]
RP   RETRACTED PAPER.
RX   PubMed=22105604; DOI=10.2119/molmed.2011.00389;
RA   Yang H., Lundback P., Ottosson L., Erlandsson-Harris H., Venereau E.,
RA   Bianchi M.E., Al-Abed Y., Andersson U., Tracey K.J., Antoine D.J.;
RT   "Redox modification of cysteine residues regulates the cytokine activity of
RT   high mobility group box-1 (HMGB1).";
RL   Mol. Med. 18:250-259(2012).
RN   [28]
RP   RETRACTION NOTICE OF PUBMED:22105604.
RX   PubMed=33380312; DOI=10.1186/s10020-020-00264-1;
RA   Yang H., Lundbaeck P., Ottosson L., Erlandsson-Harris H., Venereau E.,
RA   Bianchi M.E., Al-Abed Y., Andersson U., Tracey K.J., Antoine D.J.;
RT   "Retraction Note to: Redox modification of cysteine residues regulates the
RT   cytokine activity of high mobility group box-1 (HMGB1).";
RL   Mol. Med. 26:133-133(2020).
RN   [29]
RP   REVIEW ON FUNCTION RELATED TO ADAPTIVE IMMUNITY.
RX   PubMed=23519706; DOI=10.3389/fimmu.2013.00068;
RA   Li G., Liang X., Lotze M.T.;
RT   "HMGB1: The central cytokine for all lymphoid cells.";
RL   Front. Immunol. 4:68-68(2013).
RN   [30]
RP   REVIEW ON FUNCTION RELATED TO INFLAMMATION.
RX   PubMed=23446148; DOI=10.1189/jlb.1212662;
RA   Yang H., Antoine D.J., Andersson U., Tracey K.J.;
RT   "The many faces of HMGB1: molecular structure-functional activity in
RT   inflammation, apoptosis, and chemotaxis.";
RL   J. Leukoc. Biol. 93:865-873(2013).
RN   [31]
RP   FUNCTION.
RX   PubMed=23508573; DOI=10.2119/molmed.2012.00306;
RA   Kim S., Kim S.Y., Pribis J.P., Lotze M., Mollen K.P., Shapiro R.,
RA   Loughran P., Scott M.J., Billiar T.R.;
RT   "Signaling of high mobility group box 1 (HMGB1) through toll-like receptor
RT   4 in macrophages requires CD14.";
RL   Mol. Med. 19:88-98(2013).
RN   [32]
RP   REVIEW.
RX   PubMed=23994764; DOI=10.1016/j.semcancer.2013.08.002;
RA   Li G., Tang D., Lotze M.T.;
RT   "Menage a Trois in stress: DAMPs, redox and autophagy.";
RL   Semin. Cancer Biol. 23:380-390(2013).
RN   [33]
RP   FUNCTION, AND REDOX FORMS.
RX   PubMed=24551219; DOI=10.1371/journal.pone.0089070;
RA   Polanska E., Pospisilova S., Stros M.;
RT   "Binding of histone H1 to DNA is differentially modulated by redox state of
RT   HMGB1.";
RL   PLoS ONE 9:E89070-E89070(2014).
RN   [34]
RP   REVIEW ON FUNCTION RELATED TO INNATE IMMUNITY.
RX   PubMed=25048472; DOI=10.3349/ymj.2014.55.5.1165;
RA   Lee S.A., Kwak M.S., Kim S., Shin J.S.;
RT   "The role of high mobility group box 1 in innate immunity.";
RL   Yonsei Med. J. 55:1165-1176(2014).
RN   [35]
RP   STRUCTURE BY NMR OF 88-165.
RX   PubMed=8467791; DOI=10.1002/j.1460-2075.1993.tb05776.x;
RA   Weir H.M., Kraulis P.J., Hill C.S., Raine A.R.C., Laue E.D., Thomas J.O.;
RT   "Structure of the HMG box motif in the B-domain of HMG1.";
RL   EMBO J. 12:1311-1319(1993).
RN   [36]
RP   STRUCTURE BY NMR OF 1-84.
RC   STRAIN=Sprague-Dawley;
RX   PubMed=8527432; DOI=10.1021/bi00051a007;
RA   Hardman C.H., Broadhurst R.W., Raine A.R.C., Grasser K.D., Thomas J.O.,
RA   Laue E.D.;
RT   "Structure of the A-domain of HMG1 and its interaction with DNA as studied
RT   by heteronuclear three- and four-dimensional NMR spectroscopy.";
RL   Biochemistry 34:16596-16607(1995).
CC   -!- FUNCTION: Multifunctional redox sensitive protein with various roles in
CC       different cellular compartments. In the nucleus is one of the major
CC       chromatin-associated non-histone proteins and acts as a DNA chaperone
CC       involved in replication, transcription, chromatin remodeling, V(D)J
CC       recombination, DNA repair and genome stability. Proposed to be an
CC       universal biosensor for nucleic acids. Promotes host inflammatory
CC       response to sterile and infectious signals and is involved in the
CC       coordination and integration of innate and adaptive immune responses.
CC       In the cytoplasm functions as a sensor and/or chaperone for immunogenic
CC       nucleic acids implicating the activation of TLR9-mediated immune
CC       responses, and mediates autophagy. Acts as a danger-associated
CC       molecular pattern (DAMP) molecule that amplifies immune responses
CC       during tissue injury. Released to the extracellular environment can
CC       bind DNA, nucleosomes, IL-1 beta, CXCL12, AGER isoform 2/sRAGE,
CC       lipopolysaccharide (LPS) and lipoteichoic acid (LTA), and activates
CC       cells through engagement of multiple surface receptors. In the
CC       extracellular compartment fully reduced HMGB1 (released by necrosis)
CC       acts as a chemokine, disulfide HMGB1 (actively secreted) as a cytokine,
CC       and sulfonyl HMGB1 (released from apoptotic cells) promotes
CC       immunological tolerance (PubMed:23446148, PubMed:23519706,
CC       PubMed:23994764, PubMed:25048472). Has proangiogenic activity. May be
CC       involved in platelet activation. Binds to phosphatidylserine and
CC       phosphatidylethanolamide (PubMed:11154118). Bound to RAGE mediates
CC       signaling for neuronal outgrowth (PubMed:12183440, PubMed:1885601,
CC       PubMed:2461949, PubMed:7592757). May play a role in accumulation of
CC       expanded polyglutamine (polyQ) proteins. {ECO:0000250|UniProtKB:P09429,
CC       ECO:0000250|UniProtKB:P10103, ECO:0000250|UniProtKB:P63158,
CC       ECO:0000269|PubMed:11154118, ECO:0000269|PubMed:12183440,
CC       ECO:0000269|PubMed:1885601, ECO:0000269|PubMed:2461949,
CC       ECO:0000269|PubMed:7592757, ECO:0000305|PubMed:23446148,
CC       ECO:0000305|PubMed:23519706, ECO:0000305|PubMed:23994764,
CC       ECO:0000305|PubMed:25048472}.
CC   -!- FUNCTION: Nuclear functions are attributed to fully reduced HGMB1.
CC       Associates with chromatin and binds DNA with a preference to non-
CC       canonical DNA structures such as single-stranded DNA, DNA-containing
CC       cruciforms or bent structures, supercoiled DNA and ZDNA
CC       (PubMed:11513603, PubMed:2922595). Can bent DNA and enhance DNA
CC       flexibility by looping thus providing a mechanism to promote activities
CC       on various gene promoters by enhancing transcription factor binding
CC       and/or bringing distant regulatory sequences into close proximity
CC       (PubMed:12486007). May be involved in nucleotide excision repair (NER),
CC       mismatch repair (MMR) and base excision repair (BER) pathways, and
CC       double strand break repair such as non-homologous end joining (NHEJ)
CC       (PubMed:10866811). Involved in V(D)J recombination by acting as a
CC       cofactor of the RAG complex: acts by stimulating cleavage and RAG
CC       protein binding at the 23 bp spacer of conserved recombination signal
CC       sequences (RSS) (By similarity). In vitro can displace histone H1 from
CC       highly bent DNA (PubMed:24551219). Can restructure the canonical
CC       nucleosome leading to relaxation of structural constraints for
CC       transcription factor-binding (By similarity). Enhances binding of
CC       sterol regulatory element-binding proteins (SREBPs) such as SREBF1 to
CC       their cognate DNA sequences and increases their transcriptional
CC       activities (By similarity). Facilitates binding of TP53 to DNA (By
CC       similarity). May be involved in mitochondrial quality control and
CC       autophagy in a transcription-dependent fashion implicating HSPB1 (By
CC       similarity). Can modulate the activity of the telomerase complex and
CC       may be involved in telomere maintenance (By similarity).
CC       {ECO:0000250|UniProtKB:P09429, ECO:0000250|UniProtKB:P10103,
CC       ECO:0000250|UniProtKB:P63158, ECO:0000269|PubMed:10866811,
CC       ECO:0000269|PubMed:11513603, ECO:0000269|PubMed:12486007,
CC       ECO:0000269|PubMed:24551219, ECO:0000269|PubMed:2922595}.
CC   -!- FUNCTION: In the cytoplasm proposed to dissociate the BECN1:BCL2
CC       complex via competitive interaction with BECN1 leading to autophagy
CC       activation (By similarity). Can protect BECN1 and ATG5 from calpain-
CC       mediated cleavage and thus proposed to control their proautophagic and
CC       proapoptotic functions and to regulate the extent and severity of
CC       inflammation-associated cellular injury (By similarity). In myeloid
CC       cells has a protective role against endotoxemia and bacterial infection
CC       by promoting autophagy (By similarity). Involved in endosomal
CC       translocation and activation of TLR9 in response to CpG-DNA in
CC       macrophages (By similarity). {ECO:0000250|UniProtKB:P09429,
CC       ECO:0000250|UniProtKB:P63158}.
CC   -!- FUNCTION: In the extracellular compartment (following either active
CC       secretion or passive release) involved in regulation of the
CC       inflammatory response. Fully reduced HGMB1 (which subsequently gets
CC       oxidized after release) in association with CXCL12 mediates the
CC       recruitment of inflammatory cells during the initial phase of tissue
CC       injury; the CXCL12:HMGB1 complex triggers CXCR4 homodimerization
CC       (PubMed:22869893). Induces the migration of monocyte-derived immature
CC       dendritic cells and seems to regulate adhesive and migratory functions
CC       of neutrophils implicating AGER/RAGE and ITGAM (By similarity). Can
CC       bind to various types of DNA and RNA including microbial unmethylated
CC       CpG-DNA to enhance the innate immune response to nucleic acids.
CC       Proposed to act in promiscuous DNA/RNA sensing which cooperates with
CC       subsequent discriminative sensing by specific pattern recognition
CC       receptors. Promotes extracellular DNA-induced AIM2 inflammasome
CC       activation implicating AGER/RAGE (By similarity). Disulfide HMGB1 binds
CC       to transmembrane receptors, such as AGER/RAGE, TLR2, TLR4 and probably
CC       TREM1, thus activating their signal transduction pathways. Mediates the
CC       release of cytokines/chemokines such as TNF, IL-1, IL-6, IL-8, CCL2,
CC       CCL3, CCL4 and CXCL10 (PubMed:10952726, PubMed:20547845,
CC       PubMed:22869893). Promotes secretion of interferon-gamma by macrophage-
CC       stimulated natural killer (NK) cells in concert with other cytokines
CC       like IL-2 or IL-12. TLR4 is proposed to be the primary receptor
CC       promoting macrophage activation and signaling through TLR4 seems to
CC       implicate LY96/MD-2 (By similarity). In bacterial LPS- or LTA-mediated
CC       inflammatory responses binds to the endotoxins and transfers them to
CC       CD14 for signaling to the respective TLR4:LY96 and TLR2 complexes
CC       (PubMed:23508573). Contributes to tumor proliferation by association
CC       with ACER/RAGE (PubMed:10830965). Can bind to IL1-beta and signals
CC       through the IL1R1:IL1RAP receptor complex (By similarity). Binding to
CC       class A CpG activates cytokine production in plasmacytoid dendritic
CC       cells implicating TLR9, MYD88 and AGER/RAGE and can activate
CC       autoreactive B cells (By similarity). Via HMGB1-containing chromatin
CC       immune complexes may also promote B cell responses to endogenous TLR9
CC       ligands through a B-cell receptor (BCR)-dependent and ACER/RAGE-
CC       independent mechanism (By similarity). Inhibits phagocytosis of
CC       apoptotic cells by macrophages; the function is dependent on poly-ADP-
CC       ribosylation and involves binding to phosphatidylserine on the cell
CC       surface of apoptotic cells (By similarity). In adaptive immunity may be
CC       involved in enhancing immunity through activation of effector T-cells
CC       and suppression of regulatory T (TReg) cells (By similarity). In
CC       contrast, without implicating effector or regulatory T-cells, required
CC       for tumor infiltration and activation of T-cells expressing the
CC       lymphotoxin LTA:LTB heterotrimer thus promoting tumor malignant
CC       progression (By similarity). Also reported to limit proliferation of T-
CC       cells (PubMed:18277947). Released HMGB1:nucleosome complexes formed
CC       during apoptosis can signal through TLR2 to induce cytokine production.
CC       Involved in induction of immunological tolerance by apoptotic cells;
CC       its pro-inflammatory activities when released by apoptotic cells are
CC       neutralized by reactive oxygen species (ROS)-dependent oxidation
CC       specifically on Cys-106 (By similarity). During macrophage activation
CC       by activated lymphocyte-derived self apoptotic DNA (ALD-DNA) promotes
CC       recruitment of ALD-DNA to endosomes (By similarity).
CC       {ECO:0000250|UniProtKB:P09429, ECO:0000250|UniProtKB:P10103,
CC       ECO:0000250|UniProtKB:P63158, ECO:0000269|PubMed:10830965,
CC       ECO:0000269|PubMed:10952726, ECO:0000269|PubMed:18277947,
CC       ECO:0000269|PubMed:22869893}.
CC   -!- SUBUNIT: Interacts (fully reduced HMGB1) with CXCL12; probably in a 1:2
CC       ratio involving two molecules of CXCL12, each interacting with one HMG
CC       box of HMGB1; inhibited by glycyrrhizin (PubMed:22869893). Associates
CC       with the TLR4:LY96 receptor complex (PubMed:20547845). Component of the
CC       RAG complex composed of core components RAG1 and RAG2, and associated
CC       component HMGB1 or HMGB2 (By similarity). Interacts (in cytoplasm upon
CC       starvation) with BECN1; inhibits the interaction of BECN1 and BCL2
CC       leading to promotion of autophagy (PubMed:20819940). Interacts with
CC       KPNA1; involved in nuclear import (By similarity). Interacts with AGER
CC       (PubMed:12183440). Interacts with PTPRZ1 isoform 3/phosphacan
CC       (PubMed:9507007). Interacts with SREBF1, TLR2, TLR4, TLR9, APEX1, FEN1,
CC       POLB, TERT, IL1B, MSH2, XPA, XPC, HNF1A, TP53 (By similarity).
CC       Interacts with CD24; the probable CD24:SIGLEC10 complex is proposed to
CC       inhibit HGMB1-mediated tissue damage immune response. Interacts with
CC       THBD; prevents HGMB1 interaction with ACER/RAGE and inhibits HGMB1 pro-
CC       inflammatory activity. Interacts with HAVCR2; impairs HMGB1 binding to
CC       B-DNA and likely HMGB1-mediated innate immune response (By similarity).
CC       Interacts with XPO1; mediating nuclear export (PubMed:14532127).
CC       Interacts with receptor RAGE/AGER (By similarity).
CC       {ECO:0000250|UniProtKB:P09429, ECO:0000250|UniProtKB:P63158,
CC       ECO:0000269|PubMed:12183440, ECO:0000269|PubMed:14532127,
CC       ECO:0000269|PubMed:20547845, ECO:0000269|PubMed:20819940,
CC       ECO:0000269|PubMed:22869893}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:22869893}. Cytoplasm
CC       {ECO:0000269|PubMed:22869893}. Secreted {ECO:0000269|PubMed:1885601,
CC       ECO:0000269|PubMed:22869893}. Chromosome {ECO:0000269|PubMed:12110890,
CC       ECO:0000269|PubMed:15808513}. Cell membrane
CC       {ECO:0000269|PubMed:1885601, ECO:0000269|PubMed:2461949}; Peripheral
CC       membrane protein {ECO:0000269|PubMed:1885601,
CC       ECO:0000269|PubMed:2461949}; Extracellular side
CC       {ECO:0000269|PubMed:2461949}. Endosome {ECO:0000250|UniProtKB:P63158}.
CC       Endoplasmic reticulum-Golgi intermediate compartment
CC       {ECO:0000250|UniProtKB:P63158}. Note=In basal state predominantly
CC       nuclear. Shuttles between the cytoplasm and the nucleus. Nuclear export
CC       is in part XPO1-dependent implicating NES contained in both HMG boxes 1
CC       and 2 (PubMed:14532127). Release from macrophages in the extracellular
CC       milieu requires the activation of NLRC4 or NLRP3 inflammasomes (By
CC       similarity). Passively released to the extracellular milieu from
CC       necrotic cells by diffusion, involving the fully reduced form which
CC       subsequently gets oxidized (PubMed:22869893). Actively secreted from a
CC       variety of immune and non-immune cells such as macrophages, monocytes,
CC       neutrophils, dendritic cells and natural killer cells in response to
CC       various stimuli, involving a nonconventional secretory process via
CC       secretory lysosomes. Secreted by plasma cells in response to LPS (By
CC       similarity). Associated with the plasma membrane of filipodia in
CC       process-growing cells, and also deposited into the substrate-attached
CC       material (PubMed:1885601). {ECO:0000250|UniProtKB:P63158,
CC       ECO:0000269|PubMed:14532127, ECO:0000269|PubMed:15808513,
CC       ECO:0000269|PubMed:1885601, ECO:0000269|PubMed:22869893}.
CC   -!- DOMAIN: The acidic C-terminal domain forms a flexible structure which
CC       can reversibly interact intramolecularily with the HMG boxes and
CC       modulate binding to DNA and other proteins.
CC       {ECO:0000269|PubMed:11513603, ECO:0000269|PubMed:15379539}.
CC   -!- PTM: Phosphorylated at serine residues. Phosphorylation in both NLS
CC       regions is required for cytoplasmic translocation followed by
CC       secretion. {ECO:0000250|UniProtKB:P09429}.
CC   -!- PTM: Acetylated on multiple sites upon stimulation with LPS (By
CC       similarity). Acetylation on lysine residues in the nuclear localization
CC       signals (NLS 1 and NLS 2) leads to cytoplasmic localization and
CC       subsequent secretion (PubMed:14532127). Acetylation on Lys-3 results in
CC       preferential binding to DNA ends and impairs DNA bending activity
CC       (PubMed:17269659). {ECO:0000250|UniProtKB:P10103,
CC       ECO:0000269|PubMed:14532127, ECO:0000269|PubMed:17269659}.
CC   -!- PTM: Reduction/oxidation of cysteine residues Cys-23, Cys-45 and Cys-
CC       106 and a possible intramolecular disulfide bond involving Cys-23 and
CC       Cys-45 give rise to different redox forms with specific functional
CC       activities in various cellular compartments: 1- fully reduced HMGB1
CC       (HMGB1C23hC45hC106h), 2- disulfide HMGB1 (HMGB1C23-C45C106h) and
CC       3- sulfonyl HMGB1 (HMGB1C23soC45soC106so).
CC       {ECO:0000269|PubMed:16962095, ECO:0000269|PubMed:22869893,
CC       ECO:0000269|PubMed:24551219, ECO:0000305}.
CC   -!- PTM: Poly-ADP-ribosylated by PARP1 when secreted following stimulation
CC       with LPS. {ECO:0000250|UniProtKB:P63158}.
CC   -!- PTM: In vitro cleavage by CASP1 is liberating a HMG box 1-containing
CC       peptide which may mediate immunogenic activity; the peptide antagonizes
CC       apoptosis-induced immune tolerance. Can be proteolytically cleaved by a
CC       thrombin:thrombomodulin complex; reduces binding to heparin and pro-
CC       inflammatory activities (By similarity). {ECO:0000250|UniProtKB:P09429,
CC       ECO:0000250|UniProtKB:P10103}.
CC   -!- PTM: Forms covalent cross-links mediated by transglutaminase TGM2,
CC       between a glutamine and the epsilon-amino group of a lysine residue,
CC       forming homopolymers and heteropolymers.
CC       {ECO:0000250|UniProtKB:P09429}.
CC   -!- SIMILARITY: Belongs to the HMGB family. {ECO:0000305}.
CC   -!- CAUTION: Was reported that reduction/oxidation of cysteine residues
CC       Cys-23, Cys-45 and Cys-106 and a possible intramolecular disulfide bond
CC       involving Cys-23 and Cys-45 give rise to different redox forms with
CC       specific functional activities. However, this work was later retracted,
CC       although the roles of different redox forms in some functional
CC       activities is supported by other papers. {ECO:0000305|PubMed:22105604,
CC       ECO:0000305|PubMed:33380312}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M64986; AAA40729.1; -; mRNA.
DR   EMBL; Y00463; CAA68526.1; -; mRNA.
DR   EMBL; AF275734; AAF82799.1; -; mRNA.
DR   EMBL; BC061779; AAH61779.1; -; mRNA.
DR   EMBL; BC081839; AAH81839.1; -; mRNA.
DR   EMBL; BC088402; AAH88402.1; -; mRNA.
DR   PIR; A41175; NSRTH1.
DR   RefSeq; NP_037095.1; NM_012963.2.
DR   PDB; 1AAB; NMR; -; A=2-84.
DR   PDB; 1CKT; X-ray; 2.50 A; A=8-78.
DR   PDB; 1HME; NMR; -; A=89-165.
DR   PDB; 1HMF; NMR; -; A=89-165.
DR   PDB; 2GZK; NMR; -; A=82-165.
DR   PDB; 4QR9; X-ray; 2.00 A; A/B=8-81.
DR   PDBsum; 1AAB; -.
DR   PDBsum; 1CKT; -.
DR   PDBsum; 1HME; -.
DR   PDBsum; 1HMF; -.
DR   PDBsum; 2GZK; -.
DR   PDBsum; 4QR9; -.
DR   AlphaFoldDB; P63159; -.
DR   SASBDB; P63159; -.
DR   SMR; P63159; -.
DR   BioGRID; 247493; 7.
DR   IntAct; P63159; 2.
DR   STRING; 10116.ENSRNOP00000043407; -.
DR   MoonProt; P63159; -.
DR   CarbonylDB; P63159; -.
DR   iPTMnet; P63159; -.
DR   PhosphoSitePlus; P63159; -.
DR   jPOST; P63159; -.
DR   PaxDb; 10116-ENSRNOP00000040874; -.
DR   ABCD; P63159; 4 sequenced antibodies.
DR   Ensembl; ENSRNOT00055005819; ENSRNOP00055004369; ENSRNOG00055003707.
DR   Ensembl; ENSRNOT00060002337; ENSRNOP00060001512; ENSRNOG00060001541.
DR   Ensembl; ENSRNOT00065009537; ENSRNOP00065006847; ENSRNOG00065006245.
DR   GeneID; 25459; -.
DR   KEGG; rno:25459; -.
DR   AGR; RGD:2802; -.
DR   CTD; 3146; -.
DR   RGD; 2802; Hmgb1.
DR   eggNOG; KOG0381; Eukaryota.
DR   InParanoid; P63159; -.
DR   OrthoDB; 1222485at2759; -.
DR   PhylomeDB; P63159; -.
DR   Reactome; R-RNO-140342; Apoptosis induced DNA fragmentation.
DR   Reactome; R-RNO-445989; TAK1-dependent IKK and NF-kappa-B activation.
DR   Reactome; R-RNO-5620971; Pyroptosis.
DR   Reactome; R-RNO-5686938; Regulation of TLR by endogenous ligand.
DR   Reactome; R-RNO-6798695; Neutrophil degranulation.
DR   Reactome; R-RNO-879415; Advanced glycosylation endproduct receptor signaling.
DR   Reactome; R-RNO-933542; TRAF6 mediated NF-kB activation.
DR   EvolutionaryTrace; P63159; -.
DR   PRO; PR:P63159; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0035868; C:alphav-beta3 integrin-HMGB1 complex; ISO:RGD.
DR   GO; GO:0009986; C:cell surface; ISO:RGD.
DR   GO; GO:0000793; C:condensed chromosome; ISO:RGD.
DR   GO; GO:0005737; C:cytoplasm; ISO:RGD.
DR   GO; GO:0005829; C:cytosol; IDA:CAFA.
DR   GO; GO:0005769; C:early endosome; ISO:RGD.
DR   GO; GO:0005783; C:endoplasmic reticulum; ISO:RGD.
DR   GO; GO:0005793; C:endoplasmic reticulum-Golgi intermediate compartment; IEA:UniProtKB-SubCell.
DR   GO; GO:0005615; C:extracellular space; IDA:RGD.
DR   GO; GO:0045121; C:membrane raft; IDA:CAFA.
DR   GO; GO:0043005; C:neuron projection; ISO:RGD.
DR   GO; GO:0005634; C:nucleus; ISO:RGD.
DR   GO; GO:0017053; C:transcription repressor complex; ISO:RGD.
DR   GO; GO:0008097; F:5S rRNA binding; IDA:RGD.
DR   GO; GO:0003681; F:bent DNA binding; IDA:MGI.
DR   GO; GO:0000405; F:bubble DNA binding; ISS:AgBase.
DR   GO; GO:0019958; F:C-X-C chemokine binding; ISO:RGD.
DR   GO; GO:0010858; F:calcium-dependent protein kinase regulator activity; ISO:RGD.
DR   GO; GO:0000402; F:crossed form four-way junction DNA binding; IDA:MGI.
DR   GO; GO:0005125; F:cytokine activity; IDA:UniProtKB.
DR   GO; GO:0003684; F:damaged DNA binding; ISO:RGD.
DR   GO; GO:0008301; F:DNA binding, bending; IDA:RGD.
DR   GO; GO:0070182; F:DNA polymerase binding; ISO:RGD.
DR   GO; GO:0140297; F:DNA-binding transcription factor binding; ISO:RGD.
DR   GO; GO:0003690; F:double-stranded DNA binding; IDA:RGD.
DR   GO; GO:0003725; F:double-stranded RNA binding; ISO:RGD.
DR   GO; GO:0000400; F:four-way junction DNA binding; IDA:RGD.
DR   GO; GO:0051861; F:glycolipid binding; IDA:RGD.
DR   GO; GO:0008201; F:heparin binding; IDA:RGD.
DR   GO; GO:0005178; F:integrin binding; ISO:RGD.
DR   GO; GO:0001530; F:lipopolysaccharide binding; ISO:RGD.
DR   GO; GO:0016829; F:lyase activity; ISO:RGD.
DR   GO; GO:0003676; F:nucleic acid binding; ISO:RGD.
DR   GO; GO:0000401; F:open form four-way junction DNA binding; IDA:MGI.
DR   GO; GO:0042277; F:peptide binding; IDA:RGD.
DR   GO; GO:0001786; F:phosphatidylserine binding; ISO:RGD.
DR   GO; GO:0030295; F:protein kinase activator activity; ISO:RGD.
DR   GO; GO:0050786; F:RAGE receptor binding; IMP:RGD.
DR   GO; GO:0048018; F:receptor ligand activity; ISO:RGD.
DR   GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; ISO:RGD.
DR   GO; GO:0003697; F:single-stranded DNA binding; IDA:RGD.
DR   GO; GO:0003727; F:single-stranded RNA binding; ISO:RGD.
DR   GO; GO:0097100; F:supercoiled DNA binding; ISS:AgBase.
DR   GO; GO:0000976; F:transcription cis-regulatory region binding; ISO:RGD.
DR   GO; GO:0003713; F:transcription coactivator activity; ISO:RGD.
DR   GO; GO:0003714; F:transcription corepressor activity; ISO:RGD.
DR   GO; GO:0030036; P:actin cytoskeleton organization; IDA:RGD.
DR   GO; GO:0002218; P:activation of innate immune response; ISO:RGD.
DR   GO; GO:0043277; P:apoptotic cell clearance; ISS:UniProtKB.
DR   GO; GO:0006914; P:autophagy; IEA:UniProtKB-KW.
DR   GO; GO:0006284; P:base-excision repair; ISO:RGD.
DR   GO; GO:0000902; P:cell morphogenesis; IMP:RGD.
DR   GO; GO:0071347; P:cellular response to interleukin-1; IEP:RGD.
DR   GO; GO:0098761; P:cellular response to interleukin-7; ISO:RGD.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; ISO:RGD.
DR   GO; GO:0006935; P:chemotaxis; IDA:RGD.
DR   GO; GO:0006325; P:chromatin organization; ISO:RGD.
DR   GO; GO:0007623; P:circadian rhythm; IEP:RGD.
DR   GO; GO:0032392; P:DNA geometric change; IDA:MGI.
DR   GO; GO:0035767; P:endothelial cell chemotaxis; ISO:RGD.
DR   GO; GO:0001935; P:endothelial cell proliferation; ISO:RGD.
DR   GO; GO:0001654; P:eye development; ISO:RGD.
DR   GO; GO:0005980; P:glycogen catabolic process; ISO:RGD.
DR   GO; GO:0031507; P:heterochromatin formation; ISO:RGD.
DR   GO; GO:0050930; P:induction of positive chemotaxis; IDA:MGI.
DR   GO; GO:0006954; P:inflammatory response; ISO:RGD.
DR   GO; GO:0002437; P:inflammatory response to antigenic stimulus; ISO:RGD.
DR   GO; GO:0030324; P:lung development; ISO:RGD.
DR   GO; GO:0002281; P:macrophage activation involved in immune response; ISO:RGD.
DR   GO; GO:0050831; P:male-specific defense response to bacterium; IDA:RGD.
DR   GO; GO:0030099; P:myeloid cell differentiation; ISO:RGD.
DR   GO; GO:0001773; P:myeloid dendritic cell activation; ISO:RGD.
DR   GO; GO:0002318; P:myeloid progenitor cell differentiation; ISO:RGD.
DR   GO; GO:0051450; P:myoblast proliferation; IMP:RGD.
DR   GO; GO:2000426; P:negative regulation of apoptotic cell clearance; ISO:RGD.
DR   GO; GO:0043537; P:negative regulation of blood vessel endothelial cell migration; ISO:RGD.
DR   GO; GO:0043371; P:negative regulation of CD4-positive, alpha-beta T cell differentiation; ISO:RGD.
DR   GO; GO:0008156; P:negative regulation of DNA replication; IDA:RGD.
DR   GO; GO:0017055; P:negative regulation of RNA polymerase II transcription preinitiation complex assembly; ISO:RGD.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; ISO:RGD.
DR   GO; GO:0032689; P:negative regulation of type II interferon production; ISO:RGD.
DR   GO; GO:0007399; P:nervous system development; IMP:RGD.
DR   GO; GO:0051402; P:neuron apoptotic process; IMP:RGD.
DR   GO; GO:0031175; P:neuron projection development; IGI:UniProtKB.
DR   GO; GO:0097350; P:neutrophil clearance; ISS:UniProtKB.
DR   GO; GO:0002270; P:plasmacytoid dendritic cell activation; ISO:RGD.
DR   GO; GO:0042104; P:positive regulation of activated T cell proliferation; ISO:RGD.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IMP:RGD.
DR   GO; GO:0010508; P:positive regulation of autophagy; IMP:RGD.
DR   GO; GO:0043536; P:positive regulation of blood vessel endothelial cell migration; ISO:RGD.
DR   GO; GO:0030335; P:positive regulation of cell migration; IDA:MGI.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:RGD.
DR   GO; GO:2000343; P:positive regulation of chemokine (C-X-C motif) ligand 2 production; ISO:RGD.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; ISO:RGD.
DR   GO; GO:2001200; P:positive regulation of dendritic cell differentiation; ISO:RGD.
DR   GO; GO:0051106; P:positive regulation of DNA ligation; IDA:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; ISO:RGD.
DR   GO; GO:0045819; P:positive regulation of glycogen catabolic process; ISO:RGD.
DR   GO; GO:0045089; P:positive regulation of innate immune response; ISO:RGD.
DR   GO; GO:0032727; P:positive regulation of interferon-alpha production; ISO:RGD.
DR   GO; GO:0032728; P:positive regulation of interferon-beta production; ISO:RGD.
DR   GO; GO:0032731; P:positive regulation of interleukin-1 beta production; ISO:RGD.
DR   GO; GO:0032732; P:positive regulation of interleukin-1 production; IDA:UniProtKB.
DR   GO; GO:0032733; P:positive regulation of interleukin-10 production; ISO:RGD.
DR   GO; GO:0032735; P:positive regulation of interleukin-12 production; ISO:RGD.
DR   GO; GO:0032755; P:positive regulation of interleukin-6 production; IDA:UniProtKB.
DR   GO; GO:0032757; P:positive regulation of interleukin-8 production; IDA:UniProtKB.
DR   GO; GO:0046330; P:positive regulation of JNK cascade; ISO:RGD.
DR   GO; GO:0071642; P:positive regulation of macrophage inflammatory protein 1 alpha production; IDA:UniProtKB.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; ISO:RGD.
DR   GO; GO:0002053; P:positive regulation of mesenchymal cell proliferation; IDA:MGI.
DR   GO; GO:0032425; P:positive regulation of mismatch repair; ISO:RGD.
DR   GO; GO:0045931; P:positive regulation of mitotic cell cycle; IDA:MGI.
DR   GO; GO:0071639; P:positive regulation of monocyte chemotactic protein-1 production; ISO:RGD.
DR   GO; GO:0090026; P:positive regulation of monocyte chemotaxis; ISO:RGD.
DR   GO; GO:0033034; P:positive regulation of myeloid cell apoptotic process; IDA:RGD.
DR   GO; GO:0045639; P:positive regulation of myeloid cell differentiation; ISO:RGD.
DR   GO; GO:1905455; P:positive regulation of myeloid progenitor cell differentiation; ISO:RGD.
DR   GO; GO:0045663; P:positive regulation of myoblast differentiation; IMP:RGD.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; IMP:RGD.
DR   GO; GO:1901224; P:positive regulation of non-canonical NF-kappaB signal transduction; ISO:RGD.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; ISO:RGD.
DR   GO; GO:0014911; P:positive regulation of smooth muscle cell migration; IDA:RGD.
DR   GO; GO:1903672; P:positive regulation of sprouting angiogenesis; ISO:RGD.
DR   GO; GO:0034137; P:positive regulation of toll-like receptor 2 signaling pathway; ISO:RGD.
DR   GO; GO:0034145; P:positive regulation of toll-like receptor 4 signaling pathway; ISO:RGD.
DR   GO; GO:0034165; P:positive regulation of toll-like receptor 9 signaling pathway; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; ISO:RGD.
DR   GO; GO:0032760; P:positive regulation of tumor necrosis factor production; IDA:UniProtKB.
DR   GO; GO:1905564; P:positive regulation of vascular endothelial cell proliferation; ISO:RGD.
DR   GO; GO:0090303; P:positive regulation of wound healing; ISO:RGD.
DR   GO; GO:0065003; P:protein-containing complex assembly; IDA:RGD.
DR   GO; GO:2000819; P:regulation of nucleotide-excision repair; ISO:RGD.
DR   GO; GO:0002840; P:regulation of T cell mediated immune response to tumor cell; ISS:UniProtKB.
DR   GO; GO:0002643; P:regulation of tolerance induction; ISO:RGD.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   GO; GO:0051384; P:response to glucocorticoid; ISO:RGD.
DR   GO; GO:0009749; P:response to glucose; IEP:RGD.
DR   GO; GO:0032868; P:response to insulin; IEP:RGD.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IEP:RGD.
DR   GO; GO:0034341; P:response to type II interferon; IMP:RGD.
DR   GO; GO:0009410; P:response to xenobiotic stimulus; IEP:RGD.
DR   GO; GO:0035711; P:T-helper 1 cell activation; ISO:RGD.
DR   GO; GO:0045063; P:T-helper 1 cell differentiation; ISO:RGD.
DR   GO; GO:0006366; P:transcription by RNA polymerase II; ISO:RGD.
DR   GO; GO:0033151; P:V(D)J recombination; ISO:RGD.
DR   CDD; cd21978; HMG-box_HMGB_rpt1; 1.
DR   CDD; cd21979; HMG-box_HMGB_rpt2; 1.
DR   DisProt; DP02138; -.
DR   Gene3D; 1.10.30.10; High mobility group box domain; 2.
DR   InterPro; IPR009071; HMG_box_dom.
DR   InterPro; IPR036910; HMG_box_dom_sf.
DR   InterPro; IPR017967; HMG_boxA_CS.
DR   InterPro; IPR050342; HMGB.
DR   PANTHER; PTHR48112:SF12; HIGH MOBILITY GROUP PROTEIN B1; 1.
DR   PANTHER; PTHR48112; HIGH MOBILITY GROUP PROTEIN DSP1; 1.
DR   Pfam; PF00505; HMG_box; 1.
DR   Pfam; PF09011; HMG_box_2; 1.
DR   PRINTS; PR00886; HIGHMOBLTY12.
DR   SMART; SM00398; HMG; 2.
DR   SUPFAM; SSF47095; HMG-box; 2.
DR   PROSITE; PS00353; HMG_BOX_1; 1.
DR   PROSITE; PS50118; HMG_BOX_2; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Adaptive immunity; ADP-ribosylation; Autophagy;
KW   Cell membrane; Chemotaxis; Chromosome; Cytoplasm;
KW   Direct protein sequencing; Disulfide bond; DNA damage; DNA recombination;
KW   DNA repair; DNA-binding; Endosome; Heparin-binding; Immunity;
KW   Inflammatory response; Innate immunity; Isopeptide bond; Membrane; Nucleus;
KW   Oxidation; Phosphoprotein; Reference proteome; Repeat; Secreted.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000269|PubMed:2461949"
FT   CHAIN           2..215
FT                   /note="High mobility group protein B1"
FT                   /id="PRO_0000048530"
FT   DNA_BIND        9..79
FT                   /note="HMG box 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00267"
FT   DNA_BIND        95..163
FT                   /note="HMG box 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00267"
FT   REGION          2..97
FT                   /note="Sufficient for interaction with HAVCR2"
FT                   /evidence="ECO:0000250|UniProtKB:P63158"
FT   REGION          3..15
FT                   /note="LPS binding (delipidated)"
FT                   /evidence="ECO:0000250|UniProtKB:P09429"
FT   REGION          76..95
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          80..96
FT                   /note="LPS binding (Lipid A)"
FT                   /evidence="ECO:0000250|UniProtKB:P09429"
FT   REGION          89..108
FT                   /note="Cytokine-stimulating activity"
FT                   /evidence="ECO:0000250|UniProtKB:P09429"
FT   REGION          150..183
FT                   /note="Binding to AGER/RAGE"
FT                   /evidence="ECO:0000269|PubMed:12183440"
FT   REGION          161..215
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           27..43
FT                   /note="Nuclear localization signal (NLS) 1"
FT                   /evidence="ECO:0000269|PubMed:14532127"
FT   MOTIF           178..184
FT                   /note="Nuclear localization signal (NLS) 2"
FT                   /evidence="ECO:0000269|PubMed:14532127"
FT   COMPBIAS        76..94
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        161..187
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        188..215
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         2..10
FT                   /ligand="heparin"
FT                   /ligand_id="ChEBI:CHEBI:28304"
FT                   /evidence="ECO:0000250|UniProtKB:P10103"
FT   SITE            10..11
FT                   /note="Cleavage; by thrombin:thrombomodulin"
FT                   /evidence="ECO:0000250|UniProtKB:P10103"
FT   SITE            67..68
FT                   /note="Cleavage; by CASP1"
FT                   /evidence="ECO:0000250|UniProtKB:P09429"
FT   MOD_RES         3
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:17269659"
FT   MOD_RES         7
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P10103"
FT   MOD_RES         8
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P10103"
FT   MOD_RES         12
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P10103"
FT   MOD_RES         23
FT                   /note="Cysteine sulfonic acid (-SO3H); alternate"
FT                   /evidence="ECO:0000305|PubMed:22869893"
FT   MOD_RES         28
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P10103"
FT   MOD_RES         29
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P10103"
FT   MOD_RES         30
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P10103"
FT   MOD_RES         35
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P09429"
FT   MOD_RES         43
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P63158"
FT   MOD_RES         45
FT                   /note="Cysteine sulfonic acid (-SO3H); alternate"
FT                   /evidence="ECO:0000305|PubMed:22869893"
FT   MOD_RES         90
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P63158"
FT   MOD_RES         100
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P09429"
FT   MOD_RES         106
FT                   /note="Cysteine sulfonic acid (-SO3H)"
FT                   /evidence="ECO:0000305|PubMed:22869893"
FT   MOD_RES         127
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P10103"
FT   MOD_RES         128
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P10103"
FT   MOD_RES         141
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P63158"
FT   MOD_RES         172
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P10103"
FT   MOD_RES         173
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P10103"
FT   MOD_RES         177
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P10103"
FT   MOD_RES         180
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P10103"
FT   MOD_RES         181
FT                   /note="ADP-ribosylserine"
FT                   /evidence="ECO:0000250|UniProtKB:P09429"
FT   MOD_RES         182
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P10103"
FT   MOD_RES         183
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P10103"
FT   MOD_RES         184
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P10103"
FT   MOD_RES         185
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P10103"
FT   DISULFID        23..45
FT                   /note="In disulfide HMGB1; alternate"
FT                   /evidence="ECO:0000269|PubMed:16962095,
FT                   ECO:0000269|PubMed:22869893, ECO:0000269|PubMed:24551219"
FT   CROSSLNK        28
FT                   /note="Isoglutamyl lysine isopeptide (Lys-Gln) (interchain
FT                   with Q-?)"
FT                   /evidence="ECO:0000250|UniProtKB:P09429"
FT   CROSSLNK        43
FT                   /note="Isoglutamyl lysine isopeptide (Lys-Gln) (interchain
FT                   with Q-?)"
FT                   /evidence="ECO:0000250|UniProtKB:P09429"
FT   CROSSLNK        44
FT                   /note="Isoglutamyl lysine isopeptide (Lys-Gln) (interchain
FT                   with Q-?)"
FT                   /evidence="ECO:0000250|UniProtKB:P09429"
FT   CROSSLNK        68
FT                   /note="Isoglutamyl lysine isopeptide (Lys-Gln) (interchain
FT                   with Q-?)"
FT                   /evidence="ECO:0000250|UniProtKB:P09429"
FT   CROSSLNK        180
FT                   /note="Isoglutamyl lysine isopeptide (Lys-Gln) (interchain
FT                   with Q-?)"
FT                   /evidence="ECO:0000250|UniProtKB:P09429"
FT   CROSSLNK        182
FT                   /note="Isoglutamyl lysine isopeptide (Lys-Gln) (interchain
FT                   with Q-?)"
FT                   /evidence="ECO:0000250|UniProtKB:P09429"
FT   CROSSLNK        183
FT                   /note="Isoglutamyl lysine isopeptide (Lys-Gln) (interchain
FT                   with Q-?)"
FT                   /evidence="ECO:0000250|UniProtKB:P09429"
FT   CROSSLNK        184
FT                   /note="Isoglutamyl lysine isopeptide (Lys-Gln) (interchain
FT                   with Q-?)"
FT                   /evidence="ECO:0000250|UniProtKB:P09429"
FT   MUTAGEN         23
FT                   /note="C->S: No effect on nuclear localization. Decreases
FT                   interaction with BCN1 and impairs in autophagy induction.
FT                   Abolishes cytokine-stimulating activity and no effect on
FT                   chemoattractant activity; when associated with S-45."
FT                   /evidence="ECO:0000269|PubMed:16962095,
FT                   ECO:0000269|PubMed:20819940, ECO:0000269|PubMed:22869893"
FT   MUTAGEN         28..30
FT                   /note="KKK->AAA: Partial cytoplasmic localization; when
FT                   associated with 181-A--A-183."
FT                   /evidence="ECO:0000269|PubMed:14532127"
FT   MUTAGEN         28..30
FT                   /note="KKK->QQQ: Partial cytoplasmic localization (mimicks
FT                   acetylation); when associated with 181-Q--Q-183."
FT                   /evidence="ECO:0000269|PubMed:14532127"
FT   MUTAGEN         38
FT                   /note="F->A: Disrupts association with chromatin; when
FT                   associated A-103 and A-122."
FT                   /evidence="ECO:0000269|PubMed:15808513"
FT   MUTAGEN         45
FT                   /note="C->S: No effect on nuclear localization. Decreases
FT                   interaction with BCN1 and impairs autophagy induction.
FT                   Abolishes cytokine-stimulating activity and no effect on
FT                   chemoattractant activity; when associated with S-23."
FT                   /evidence="ECO:0000269|PubMed:16962095,
FT                   ECO:0000269|PubMed:20819940, ECO:0000269|PubMed:22869893"
FT   MUTAGEN         103
FT                   /note="F->A: Disrupts association with chromatin; when
FT                   associated A-38 and A-122."
FT                   /evidence="ECO:0000269|PubMed:15808513"
FT   MUTAGEN         106
FT                   /note="C->A: Disrupts interaction with TLR4:LY96 receptor
FT                   complex and abolishes TNF release from macrophages."
FT                   /evidence="ECO:0000269|PubMed:20547845"
FT   MUTAGEN         106
FT                   /note="C->S: Abolishes cytokine-stimulating activity; no
FT                   effect on chemoattractant activity; impaired nuclear and
FT                   enhanced cytoplasmic localization, retained activity in
FT                   autophagy regulation."
FT                   /evidence="ECO:0000269|PubMed:16962095,
FT                   ECO:0000269|PubMed:20819940, ECO:0000269|PubMed:22869893"
FT   MUTAGEN         122
FT                   /note="I->A: Disrupts association with chromatin; when
FT                   associated A-38 and A-103."
FT                   /evidence="ECO:0000269|PubMed:15808513"
FT   MUTAGEN         182..184
FT                   /note="KKK->AAA: Partial cytoplasmic localization; when
FT                   associated with 27-A--A-29."
FT                   /evidence="ECO:0000269|PubMed:14532127"
FT   MUTAGEN         182..184
FT                   /note="KKK->QQQ: Partial cytoplasmic localization (mimicks
FT                   acetylation); when associated with 27-Q--Q-29."
FT                   /evidence="ECO:0000269|PubMed:14532127"
FT   HELIX           15..30
FT                   /evidence="ECO:0007829|PDB:4QR9"
FT   TURN            32..34
FT                   /evidence="ECO:0007829|PDB:1AAB"
FT   HELIX           38..51
FT                   /evidence="ECO:0007829|PDB:4QR9"
FT   HELIX           54..76
FT                   /evidence="ECO:0007829|PDB:4QR9"
FT   HELIX           86..88
FT                   /evidence="ECO:0007829|PDB:2GZK"
FT   HELIX           103..116
FT                   /evidence="ECO:0007829|PDB:1HME"
FT   HELIX           122..135
FT                   /evidence="ECO:0007829|PDB:1HME"
FT   HELIX           138..140
FT                   /evidence="ECO:0007829|PDB:1HME"
FT   HELIX           142..159
FT                   /evidence="ECO:0007829|PDB:1HME"
SQ   SEQUENCE   215 AA;  24894 MW;  8A868DE266D552B5 CRC64;
     MGKGDPKKPR GKMSSYAFFV QTCREEHKKK HPDASVNFSE FSKKCSERWK TMSAKEKGKF
     EDMAKADKAR YEREMKTYIP PKGETKKKFK DPNAPKRPPS AFFLFCSEYR PKIKGEHPGL
     SIGDVAKKLG EMWNNTAADD KQPYEKKAAK LKEKYEKDIA AYRAKGKPDA AKKGVVKAEK
     SKKKKEEEDD EEDEEDEEEE EEEEDEDEEE DDDDE
//
